Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 331

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

Open access
Sharma, Ankur, Yeow, Wen-Shuz, Ertel, Adam, Coleman, Ilsa, Clegg, Nigel, Thangavel, Chellappagounder, Morrissey, Colm, Zhang, Xiaotun, Comstock, Clay E.S., Witkiewicz, Agnieszka K., Gomella, Leonard, Knudsen, Erik S., Nelson, Peter S., Knudsen, Karen E.·2010·Journal of Clinical Investigation

Abstract

Retinoblastoma (RB; encoded by RB1) is a tumor suppressor that is frequently disrupted in tumorigenesis and acts in multiple cell types to suppress cell cycle progression. The role of RB in tumor progression, however, is poorly defined. Here, we have identified a critical role for RB in protecting against tumor progression through regulation of targets distinct from cell cycle control. In analyses of human prostate cancer samples, RB loss was infrequently observed in primary disease and was predominantly associated with transition to the incurable, castration-resistant state. Further analyses revealed that loss of the RB1 locus may be a major mechanism of RB disruption and that loss of RB function was associated with poor clinical outcome. Modeling of RB dysfunction in vitro and in vivo revealed that RB controlled nuclear receptor networks critical for tumor progression and that it did so via E2F transcription factor 1-mediated regulation of androgen receptor (AR) expression and output. Through this pathway, RB depletion induced unchecked AR activity that underpinned therapeutic bypass and tumor progression. In agreement with these findings, disruption of the RB/E2F/nuclear receptor axis was frequently observed in the transition to therapy resistance in human disease. Together, these data reveal what we believe to be a new paradigm for RB function in controlling prostate tumor progression and lethal tumor phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci44239

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 331

Metadata

Authors
Sharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., Gomella, L., Knudsen, E. S., Nelson, P. S., & Knudsen, K. E.
Venue
Journal of Clinical Investigation
Published
2010-12-01
Volume
120
Issue
12
Pages
4478-4492
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1993624611
Cited by
331
References
57
FWCI
19.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. https://app.cochat.ai/papers/10.1172/jci44239
The paper
Sharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., Gomella, L., Knudsen, E. S., Nelson, P. S., & Knudsen, K. E. (2010). The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation. https://doi.org/10.1172/jci44239

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.